FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317804319> ?p ?o ?g. }

• W4317804319 abstract "Abstract In patients on chronic hemodialysis, there is no standard protocol for maintenance iron supplementation. This study aimed to compare two fixed-dose intravenous (IV) iron protocols to reduce erythropoiesis-stimulating agents (ESA). We conducted a double-blinded, randomized controlled study on hemodialysis patients having ferritin levels between 200 and 700 ng/dl and transferrin saturation values between 20 and 40%. Patients were assigned to receive either 100 or 200 mg of IV iron each month. ESA was adjusted every month to keep Hb between 10 and 12 g/dl. ESA dose at 12 months was the primary outcome. The secondary outcomes were all-cause mortality, cardiovascular events, absolute iron deficiency anemia (IDA), blood transfusion, adverse events, and iron withholding rate. Of the 79 eligible patients, 40 received 100 mg of IV iron, while 39 received 200 mg. At month 12, the mean monthly ESA dose in the 100-mg IV iron group was 35,706 ± 21,637 IU, compared to 26,382 ± 14,983 IU in the 200-mg group ( P = 0.03). IDA was found in twelve patients (30%) in the 100-mg group and four patients (10.5%) in the 200-mg group ( P = 0.05). In each group, three patients died ( P = 0.9). Hospitalization, venous access thrombosis, and infection rates were similar in both groups. The withholding rate of IV iron was higher in 200-mg group (25% vs . 64.1%), but the protocol compliance was found more in 100-mg group (50% vs. 28.2%) ( P = 0.001). In conclusion, monthly 200-mg IV iron infusions significantly reduce ESA doses but have a higher withholding rate. (Funded by the Kidney Foundation of Thailand and the Research Group in Nephrology and Renal Replacement Therapy from the Faculty of Medicine, Thammasat University). Thai Clinical Trials Registry number, TCTR20190707001." @default.
• W4317804319 created "2023-01-24" @default.
• W4317804319 creator A5002364835 @default.
• W4317804319 creator A5005966187 @default.
• W4317804319 creator A5053977488 @default.
• W4317804319 date "2023-01-23" @default.
• W4317804319 modified "2023-09-25" @default.
• W4317804319 title "Maintenance intravenous iron in hemodialysis patients to minimize erythropoietin doses: a double-blinded, randomized controlled trial (the MAINTAIN IRON trial)" @default.
• W4317804319 cites W2023227652 @default.
• W4317804319 cites W2085784457 @default.
• W4317804319 cites W2093274439 @default.
• W4317804319 cites W2099927570 @default.
• W4317804319 cites W2133154556 @default.
• W4317804319 cites W2138609117 @default.
• W4317804319 cites W2222807855 @default.
• W4317804319 cites W2301182697 @default.
• W4317804319 cites W2580449060 @default.
• W4317804319 cites W2767839794 @default.
• W4317804319 cites W2788067661 @default.
• W4317804319 cites W2790152587 @default.
• W4317804319 cites W2898498137 @default.
• W4317804319 cites W2944434778 @default.
• W4317804319 cites W3006132236 @default.
• W4317804319 cites W3014325832 @default.
• W4317804319 cites W3036192792 @default.
• W4317804319 cites W3144773245 @default.
• W4317804319 cites W4280566096 @default.
• W4317804319 doi "https://doi.org/10.1038/s41598-023-28440-3" @default.
• W4317804319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36690782" @default.
• W4317804319 hasPublicationYear "2023" @default.
• W4317804319 type Work @default.
• W4317804319 citedByCount "0" @default.
• W4317804319 crossrefType "journal-article" @default.
• W4317804319 hasAuthorship W4317804319A5002364835 @default.
• W4317804319 hasAuthorship W4317804319A5005966187 @default.
• W4317804319 hasAuthorship W4317804319A5053977488 @default.
• W4317804319 hasBestOaLocation W43178043191 @default.
• W4317804319 hasConcept C126322002 @default.
• W4317804319 hasConcept C141071460 @default.
• W4317804319 hasConcept C153852466 @default.
• W4317804319 hasConcept C168563851 @default.
• W4317804319 hasConcept C197934379 @default.
• W4317804319 hasConcept C2777417653 @default.
• W4317804319 hasConcept C2778063415 @default.
• W4317804319 hasConcept C2778248108 @default.
• W4317804319 hasConcept C2778319317 @default.
• W4317804319 hasConcept C2778534260 @default.
• W4317804319 hasConcept C71924100 @default.
• W4317804319 hasConcept C90924648 @default.
• W4317804319 hasConceptScore W4317804319C126322002 @default.
• W4317804319 hasConceptScore W4317804319C141071460 @default.
• W4317804319 hasConceptScore W4317804319C153852466 @default.
• W4317804319 hasConceptScore W4317804319C168563851 @default.
• W4317804319 hasConceptScore W4317804319C197934379 @default.
• W4317804319 hasConceptScore W4317804319C2777417653 @default.
• W4317804319 hasConceptScore W4317804319C2778063415 @default.
• W4317804319 hasConceptScore W4317804319C2778248108 @default.
• W4317804319 hasConceptScore W4317804319C2778319317 @default.
• W4317804319 hasConceptScore W4317804319C2778534260 @default.
• W4317804319 hasConceptScore W4317804319C71924100 @default.
• W4317804319 hasConceptScore W4317804319C90924648 @default.
• W4317804319 hasIssue "1" @default.
• W4317804319 hasLocation W43178043191 @default.
• W4317804319 hasLocation W43178043192 @default.
• W4317804319 hasLocation W43178043193 @default.
• W4317804319 hasOpenAccess W4317804319 @default.
• W4317804319 hasPrimaryLocation W43178043191 @default.
• W4317804319 hasRelatedWork W2060146138 @default.
• W4317804319 hasRelatedWork W2149563487 @default.
• W4317804319 hasRelatedWork W2468424006 @default.
• W4317804319 hasRelatedWork W2885191723 @default.
• W4317804319 hasRelatedWork W2938138458 @default.
• W4317804319 hasRelatedWork W3011738174 @default.
• W4317804319 hasRelatedWork W4319778741 @default.
• W4317804319 hasRelatedWork W4379600522 @default.
• W4317804319 hasRelatedWork W908301762 @default.
• W4317804319 hasRelatedWork W2151916546 @default.
• W4317804319 hasVolume "13" @default.
• W4317804319 isParatext "false" @default.
• W4317804319 isRetracted "false" @default.
• W4317804319 workType "article" @default.